Short answer
MADRIGAL PHARMACEUTICALS, INC. (MDGL) filed an 8-K current report with the SEC on June 17, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 5.07 (Submission of Matters to a Vote of Security Holders). Stockholders approved the 2026 Stock Plan, expanding equity-based compensation capacity for employees and executives.
MADRIGAL PHARMACEUTICALS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Stockholders approved the 2026 Stock Plan, expanding equity-based compensation capacity for employees and executives
- Stockholders approved the 2026 ESPP, enabling employee share purchases and potentially increasing equity-linked compensation expense
- New deferred compensation plan effective August 1, 2026; employees may defer up to 60% of salary and 95% of annual performance bonuses
- Deferred obligations are general unsecured liabilities; rabbi trust assets remain exposed to claims from general creditors
- Dr. Rebecca Taub transitions to consultant July 1, 2026, retaining MASH advisory duties at $100,000 annually plus director compensation
Item 5.07 · Submission of Matters to a Vote of Security Holders
- Quorum established with 21,322,829 shares represented, versus 23,055,522 outstanding
- Three Class I directors re-elected through the 2029 annual meeting
- Executive compensation approved on an advisory basis, with 19,000,895 votes for
- PwC ratified as independent auditor for fiscal 2026, with 21,256,315 votes for
- 2026 Stock Plan and ESPP approved, with 19,118,851 and 19,546,766 votes for respectively
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other MADRIGAL PHARMACEUTICALS, INC. 8-K filings
Get the next MDGL 8-K as it lands
Follow MDGL for push alerts, or ask the research agent what this filing means.